vs
Esperion Therapeutics, Inc.（ESPR）与WORKIVA INC（WK）财务数据对比。点击上方公司名可切换其他公司
WORKIVA INC的季度营收约是Esperion Therapeutics, Inc.的1.5倍（$247.3M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 19.9%），过去两年WORKIVA INC的营收复合增速更高（18.0% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Workiva Inc.是一家全球知名的SaaS企业，主打云原生关联报告合规平台，支持关联数据调用与报告流程自动化，可广泛应用于财务、会计、风险及合规等多个业务场景，助力企业提升运营效率与合规管理水平。
ESPR vs WK — 直观对比
营收规模更大
WK
是对方的1.5倍
$168.4M
营收增速更快
ESPR
高出123.8%
19.9%
两年增速更快
WK
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $247.3M |
| 净利润 | — | $19.0M |
| 毛利率 | — | 80.4% |
| 营业利润率 | 50.6% | 25.8% |
| 净利率 | — | 7.7% |
| 营收同比 | 143.7% | 19.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.32 | $0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRWK
| Q1 26 | — | $247.3M | ||
| Q4 25 | $168.4M | $238.9M | ||
| Q3 25 | $87.3M | $224.2M | ||
| Q2 25 | $82.4M | $215.2M | ||
| Q1 25 | $65.0M | $206.3M | ||
| Q4 24 | $69.1M | $199.9M | ||
| Q3 24 | $51.6M | $185.6M | ||
| Q2 24 | $73.8M | $177.5M |
净利润ESPRWK
| Q1 26 | — | $19.0M | ||
| Q4 25 | — | $11.8M | ||
| Q3 25 | $-31.3M | $2.8M | ||
| Q2 25 | $-12.7M | $-19.4M | ||
| Q1 25 | $-40.5M | $-21.4M | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-29.5M | $-17.0M | ||
| Q2 24 | $-61.9M | $-17.5M |
毛利率ESPRWK
| Q1 26 | — | 80.4% | ||
| Q4 25 | — | 80.7% | ||
| Q3 25 | — | 79.3% | ||
| Q2 25 | — | 77.0% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 77.1% | ||
| Q3 24 | — | 76.5% | ||
| Q2 24 | — | 76.8% |
营业利润率ESPRWK
| Q1 26 | — | 25.8% | ||
| Q4 25 | 50.6% | 3.3% | ||
| Q3 25 | -11.4% | -1.5% | ||
| Q2 25 | 8.6% | -10.3% | ||
| Q1 25 | -34.0% | -12.0% | ||
| Q4 24 | -6.4% | -6.7% | ||
| Q3 24 | -31.0% | -11.7% | ||
| Q2 24 | 3.5% | -13.0% |
净利率ESPRWK
| Q1 26 | — | 7.7% | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | -35.9% | 1.2% | ||
| Q2 25 | -15.4% | -9.0% | ||
| Q1 25 | -62.2% | -10.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | -57.2% | -9.2% | ||
| Q2 24 | -83.9% | -9.9% |
每股收益（稀释后）ESPRWK
| Q1 26 | — | $0.33 | ||
| Q4 25 | $0.32 | $0.21 | ||
| Q3 25 | $-0.16 | $0.05 | ||
| Q2 25 | $-0.06 | $-0.35 | ||
| Q1 25 | $-0.21 | $-0.38 | ||
| Q4 24 | $-0.14 | $-0.15 | ||
| Q3 24 | $-0.15 | $-0.31 | ||
| Q2 24 | $-0.33 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $334.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | — |
| 总资产 | $465.9M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRWK
| Q1 26 | — | $334.3M | ||
| Q4 25 | $167.9M | $338.8M | ||
| Q3 25 | $92.4M | $315.9M | ||
| Q2 25 | $86.1M | $284.3M | ||
| Q1 25 | $114.6M | $242.0M | ||
| Q4 24 | $144.8M | $301.8M | ||
| Q3 24 | $144.7M | $248.2M | ||
| Q2 24 | $189.3M | $267.9M |
股东权益ESPRWK
| Q1 26 | — | — | ||
| Q4 25 | $-302.0M | $-5.4M | ||
| Q3 25 | $-451.4M | $-36.9M | ||
| Q2 25 | $-433.5M | $-66.5M | ||
| Q1 25 | $-426.2M | $-75.7M | ||
| Q4 24 | $-388.7M | $-41.7M | ||
| Q3 24 | $-370.2M | $-50.8M | ||
| Q2 24 | $-344.2M | $-77.7M |
总资产ESPRWK
| Q1 26 | — | $1.4B | ||
| Q4 25 | $465.9M | $1.5B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.3B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | $1.4B | ||
| Q3 24 | $314.1M | $1.3B | ||
| Q2 24 | $352.3M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | $25.7M |
| 自由现金流率自由现金流/营收 | — | 10.4% |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $171.9M |
8季度趋势，按日历期对齐
经营现金流ESPRWK
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $51.0M | ||
| Q3 25 | $-4.3M | $46.2M | ||
| Q2 25 | $-31.4M | $50.3M | ||
| Q1 25 | $-22.6M | $-7.4M | ||
| Q4 24 | $-35.0M | $44.0M | ||
| Q3 24 | $-35.3M | $18.9M | ||
| Q2 24 | $-7.2M | $-14.0K |
自由现金流ESPRWK
| Q1 26 | — | $25.7M | ||
| Q4 25 | — | $50.7M | ||
| Q3 25 | — | $46.1M | ||
| Q2 25 | — | $49.3M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $-35.5M | $18.7M | ||
| Q2 24 | $-7.3M | $-122.0K |
自由现金流率ESPRWK
| Q1 26 | — | 10.4% | ||
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 20.5% | ||
| Q2 25 | — | 22.9% | ||
| Q1 25 | — | -3.9% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | -68.7% | 10.1% | ||
| Q2 24 | -9.9% | -0.1% |
资本支出强度ESPRWK
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% |
现金转化率ESPRWK
| Q1 26 | — | — | ||
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WK
| Subscription and support | $225.4M | 91% |
| Other | $22.0M | 9% |
